Now Playing
|Videos|October 21, 2022
Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer
Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
3
Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD
4
FDA Approves Ropeginterferon Alfa-2b in Essential Thrombocythemia
5